Medtronic PLC Form 4 insider transactions

NYSE
Medtronic plc director Kendall J. Powell reported transactions involving ordinary shares, including an award of restricted stock units and shares withheld for tax payments.
NYSE
Medtronic plc reports a Form 4 filing detailing stock transactions by Director Kevin E. Lofton, including restricted stock unit awards and tax withholdings.
NYSE
Medtronic plc reports a transaction where Director William R. Jellison acquired 1,444 ordinary shares.
NYSE
Medtronic plc reports on insider transactions, with Director Scott C. Donnelly acquiring restricted stock units and disposing of shares for tax payments.
NYSE
Medtronic plc director Craig Arnold reported transactions involving ordinary shares, including an award of restricted stock units and shares withheld for tax payments.
NYSE
Medtronic's EVP & CFO, Thierry Pieton, reported a disposal of 2,976 ordinary shares for tax purposes, while also increasing beneficial ownership through dividend reinvestment.
NYSE
Medtronic plc's EVP and President of Cardiovascular, Harry Skip Kiil, executed pre-planned transactions, exercising stock options and selling ordinary shares.
NYSE
Medtronic's Chief Accounting Officer, Denise L. Blomquist, reported gifting 340 ordinary shares of the company.
NYSE
Medtronic's Chief Accounting Officer, Denise L. Blomquist, disposed of 148 ordinary shares to cover tax liabilities related to vested restricted stock units.
NYSE
Medtronic EVP Brett A. Wall reported the withholding of 439 ordinary shares for tax purposes related to restricted stock unit vesting.
NYSE
Medtronic EVP Michael Marinaro disposed of 1,371 ordinary shares to cover tax liabilities related to restricted stock unit vesting.
NYSE
Medtronic plc's Chairman and CEO, Geoffrey Martha, reported a disposition of 1,564 ordinary shares for tax purposes related to restricted stock unit vesting.
NYSE
Medtronic plc's EVP and President of Cardiovascular, Harry Skip Kiil, reported the withholding of 1,702 ordinary shares for tax purposes related to restricted stock unit vesting.
NYSE
Medtronic plc's Chief Accounting Officer, Denise L. Blomquist, reported the gift of 170 ordinary shares under a pre-arranged 10b5-1 plan.
NYSE
Medtronic's EVP of Global Operations and Supply Chain, Gregory L. Smith, sold 30,000 ordinary shares for approximately $3.06 million.
NYSE
Medtronic's EVP & President of Cardiovascular, Harry Skip Kiil, sold 8,605 ordinary shares for approximately $787,900 under a pre-arranged trading plan.
NYSE
Medtronic plc Director William R. Jellison acquired 5,000 ordinary shares for approximately $462,750 in open market transactions.
NYSE
Medtronic EVP Michael Marinaro disposed of 1,052 ordinary shares to cover tax obligations related to restricted stock unit vesting.
NYSE
Medtronic's SVP, Chief HR Officer, Matthew R. Walter, reported the vesting of performance share units and exercise of stock options, alongside shares withheld for tax obligations.
NYSE
Medtronic EVP Brett Wall reported the vesting of performance-based equity awards and subsequent share disposals for tax obligations.
NYSE
Medtronic's EVP of Global Operations and Supply Chain, Gregory L. Smith, reported the vesting of performance-based equity awards and subsequent share disposals for tax obligations.
NYSE
Medtronic plc's Chairman and CEO, Geoffrey Martha, reported multiple transactions involving company ordinary shares and derivative securities on August 1, 2025.
NYSE
Medtronic plc EVP Michael Marinaro reported routine transactions involving the acquisition and disposal of company ordinary shares, primarily related to RSU vesting and tax withholdings.
NYSE
Medtronic's EVP and President of Cardiovascular, Harry Skip Kiil, acquired 10,457 ordinary shares through RSU vesting and subsequently sold 7,555 shares for tax obligations.
NYSE
Medtronic's Chief Accounting Officer, Denise L. Blomquist, reported the acquisition of ordinary shares through RSU settlements and stock option exercises, alongside tax-related dispositions.
NYSE
Medtronic plc's EVP of Global Operations and Supply Chain, Gregory L. Smith, reported a pre-planned transaction involving the withholding of 1,630 ordinary shares for tax purposes related to restricted stock unit vesting.
NYSE
Medtronic plc's Senior Vice President and Chief HR Officer, Matthew R. Walter, was granted significant equity awards including restricted stock units, performance share units, and stock options, effective July 28, 2025.
NYSE
Medtronic plc's EVP and President of Neuroscience, Brett A. Wall, was granted restricted stock units, performance share units, and stock options as part of a pre-planned equity compensation package.
NYSE
Medtronic plc's EVP of Global Operations and Supply Chain, Gregory L. Smith, was granted restricted stock units, performance share units, and stock options, increasing his beneficial ownership.
NYSE
Medtronic plc's EVP, General Counsel, and Secretary, Michelle Quinn, was granted a substantial package of restricted stock units, performance share units, and stock options, aligning her compensation with future company performance.